Current clinical guidelines for NAFLD present limited pharmacological options, with only vitamin E and the PPAR-γ agonist pioglitazone being recommended by major hepatology associations for selected patient populations. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.